Bayer cleared of 'outrageous' breaches in Xarelto ads; Novartis neighbors worry about site demo plans;

@FiercePharma: Bond market pants for Pfizer vet unit's debut offering: Zoetis sets up $3.65B in debt amid final prep for IPO. More | Follow @FiercePharma

 @AlisonBFierce: FierceVaccines brings you the major FDA vaccine approvals from 2012. Special Report | Follow @AlisonBFierce

> Bayer was cleared of alleged "outrageous" breaches of the U.K. pharma industry's marketing code after officials determined that the suspect ad wasn't misleading. Report

> Neighbors to Novartis' ($NVS) site in West Sussex, England, have complained that the company has not discussed its plans to demolish some buildings, possibly to open land for sale and development. Report

> Japan's Teijin Pharma is preparing to launch Ipsen's Somatuline injection, a treatment for acromegaly and pituitary gigantism, in its home country. Report

> Bosnia's top generics maker, Bosnalijek, predicts a 15% increase in profits for 2013, on top of an 11% increase last year. Report

> The liver cancer market is expected to approach $650 million by 2018, with Bayer's Nexavar continuing to dominate the category, GBI Research found. Report

> The Institute of Medicine concluded that the traditional schedule of childhood vaccines doesn't cause health problems in children as feared. Report (sub. req.)

> A new U.S. drugmaker, Vestiq Pharmaceuticals, has launched with two marketed products bought in from other companies. Report

Biotech News

 @FierceBiotech: Popular yesterday: Buzz: $AZN reorg inspires fresh rumors of $SHPG bid. Report | Follow @FierceBiotech

@JohnCFierce: Columnist gushes over Inovio's Kim, a tireless promoter whose stock is trading at .67 and whose flu vax is in PhI. Column | Follow @JohnCFierce

@RyanMFierce: $EXEL's plethora of partnerships bearing fruit as Genentech moves melanoma drug from EXEL into PhIII. More | Follow @RyanMFierce

> FDA green-lights a flu vaccine made with new technology. Story

> Genentech launches PhIII for melanoma combo with GSK in hot pursuit. Article

> AstraZeneca shakeup pushes research chief to top of restructured MedImmune. News

Medical Device News

 @FierceMedDev: FDA plans to clamp down on all-metal hips. Article | Follow @FierceMedDev

 @DamianFierce: Big M&A morning: Stryker's ($SYK) spending $764 million on Chinese orthopedics company Trauson. Release | Follow @DamianFierce

> Stryker to buy Chinese orthopedics biz for $764M. Story

> InfraScan gains FDA backing for next-gen brain hematoma detector. Item

> Analysts: St. Jude at risk for Durata recall. Report

Vaccines News

> IOM confirms safety of childhood vaccine schedule. Report

> CDC: Flu hits epidemic level in U.S. Item

> Protein Sciences nabs Flublok approval. News

> Vaccine stakes upped as dengue dubbed fastest-spreading tropical disease. Article

> Flu vaccine, Tamiflu shortage as influenza sweeps U.S. Story

Pharma Manufacturing News

 @EricPFierce: Amgen to build $200 million monoclonal antibody plant in Singapore. Novartis building there too. More | Follow @EricPFierce

> Wisconsin report adds to drug take-back funding debate. Item

> China ups bounty for tips on counterfeiters to $48,500. Report

> Japan's Mitsui ups stake in India API maker Arch. Story

> FDA spells out user fees for generic drugs. Article

> J&J consent decree cost felt at the pharmacy. More

And Finally... The flu vaccine is not linked to fetal death, a new study found. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.